Drugs / CEA RNA pulsed dendritic cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00003432 | Jun 1998 → Nov 2002 | breast cancer | Duke University | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CEA RNA pulsed dendritic cells | “Approximately 60-90 days after the peripheral blood stem cell transplant, patients receive CEA RNA pulsed dendritic cells IV every 3 weeks for a total of 4 doses.” NCT00003432 ↗ |
| Modality | Cell therapy | “carcinoembryonic antigen RNA-pulsed DC cancer vaccine” NCT00003432 ↗ |
| Route | Intravenous | “patients receive CEA RNA pulsed dendritic cells IV” NCT00003432 ↗ |